Chordia Therapeutics Inc. (JP:190A) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Chordia Therapeutics Inc. has announced that the World Health Organization has given an International Nonproprietary Name, rogocekib, to their CLK inhibitor CTX-712, which is currently undergoing Phase 1/2 clinical trials in the U.S. This development marks a significant step towards the commercialization of CTX-712, a promising cancer therapy.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.